公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort study | Huang B.-S.; WAN-YU CHEN ; CHUN-WEI WANG ; ANN-LII CHENG ; Hong J.-H.; SUNG-HSIN KUO | Acta Dermato-Venereologica | 3 | 3 | |
1998 | Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers | KUN-HUEI YEH ; Chen C.-L.; CHIA-TUNG SHUN ; Lin J.-T.; Lee W.-J.; PO-HUANG LEE ; YAO-CHANG CHEN ; ANN-LII CHENG | Journal of Clinical Gastroenterology | 15 | 12 | |
2020 | Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma | Ying-Chun Shen ; CHIA-LANG HSU ; YUNG-MING JENG ; MING-CHIH HO ; CHENG-MAW HO ; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; REY-HENG HU ; ANN-LII CHENG | Journal of Hepatology | 35 | 35 | |
1998 | Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin | Hutson P.R.; Tutsch R.D.; Rago R.; Arzoomanian R.; Alberti D.; Pomplun M.; Church D.; Marnocha R.; ANN-LII CHENG ; Kehrli N.; Wilding G. | Clinical Cancer Research | 9 | 9 | |
2018 | Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma” | Bruix J.; ANN-LII CHENG ; Llovet J. | Journal of Hepatology | 1 | 0 | |
1998 | Research nurses for clinical trials of anti-cancer drugs: Developing a new subspecialty in Taiwan | ANN-LII CHENG ; YEUR-HUR LAI ; Yu Y.-C. | Drug Information Journal | 0 | 0 | |
2015 | The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases | YUN CHIANG ; CHIH-HSIN YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; KENG-HSUEH LAN ; ANN-LII CHENG ; SUNG-HSIN KUO | PLoS ONE | 9 | 9 | |
1993 | Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multi-drug-resistance phenotypes | Su I.?J.; ANN-LII CHENG ; TSEN-FANG TSAI ; Lay J.?D. | British Journal of Haematology | 17 | 15 | |
2000 | Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions | Wang K.-C.; ANN-LII CHENG ; Chuang S.-E.; Hsu H.-C.; Su I.-J. | Experimental Hematology | 26 | 23 | |
2008 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial | CHIUN HSU ; Hsiung C.A.; Su I.-J.; Hwang W.-S.; Wang M.-C.; Lin S.-F.; Lin T.-H.; Hsiao H.-H.; Young J.-H.; Chang M.-C.; Liao Y.-M.; Li C.-C.; Wu H.-B.; HWEI-FANG TIEN ; Chao T.-Y.; Liu T.-W.; ANN-LII CHENG ; PEI-JER CHEN | Hepatology | 273 | 243 | |
2017 | A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement | YUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU | Journal of the Formosan Medical Association | 7 | 6 | |
2022 | Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial | El-Khoueiry, Anthony B; Meyer, Tim; ANN-LII CHENG ; Rimassa, Lorenza; Sen, Suvajit; Milwee, Steven; Kelley, Robin Kate; Abou-Alfa, Ghassan K | BMC cancer | 8 | 9 | |
2021 | Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT | Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG ; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. | Journal of Gastroenterology | 7 | 7 | |
2009 | Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Faivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG | The Lancet Oncology | 257 | 232 | |
2015 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study | ANN-LII CHENG ; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. | Journal of Hepatology | 39 | 42 | |
2021 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study | Kelley, Robin Kate; Sangro, Bruno; Harris, William; Ikeda, Masafumi; Okusaka, Takuji; Kang, Yoon-Koo; Qin, Shukui; Tai, David W-M; Lim, Ho Yeong; Yau, Thomas; Yong, Wei-Peng; ANN-LII CHENG ; Gasbarrini, Antonio; Damian, Silvia; Bruix, Jordi; Borad, Mitesh; Bendell, Johanna; Kim, Tae-You; Standifer, Nathan; He, Philip; Makowsky, Mallory; Negro, Alejandra; Kudo, Masatoshi; Abou-Alfa, Ghassan K | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 237 | 215 | |
2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 17 | 13 | |
2020 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial | Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K. | ESMO open | 46 | 46 | |
2023 | Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling | YU-CHIEH TSAI ; Wang, Tzu-Yin; Hsu, Chia-Lang; WEI-CHOU LIN ; Chen, Jyun-Yu; Li, Jia-Hua; YEONG-SHIAU PU ; ANN-LII CHENG ; CHIA-HSIEN CHENG ; SHENG-FANG SU | British journal of cancer | 4 | 4 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 54 | 44 | |